Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  CANADIAN NATIONAL STOCK EXCHANGE  >  Abattis Bioceuticals Corp    ATT   CA00258G1037

SummaryQuotesChartsNewsCompany 
News SummaryMost relevantAll newsSector newsTweets

Abattis Announces Presence at 2018 Lift Cannabis Expo and Provides Corporate Updates

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/12/2018 | 09:25pm EST

Vancouver, British Columbia--(Newsfile Corp. - January 12, 2018) - Abattis Bioceuticals Corp. (CSE: ATT) (OTCQB: ATTBF) (the "Company" or "Abattis") is pleased to announce that, along with Northern Vine Labs, it will be attending the Lift Cannabis Expo, Canada's largest and best-attended cannabis tradeshow, from January 12 to 14 at the Vancouver Convention Centre. This year's Lift Expo will feature nearly 200 exhibitors from across North America and will host talks by cannabis thought leaders, live cooking and growing demos, a vape lounge and a cannabis career fair. For more information about the Lift Expo, see www.liftexpo.ca. Northern Vine Labs is a subsidiary of Abattis and Emerald Health Therapeutics Inc.

Dr. David Galvez, Abattis's senior scientific advisor and a seasoned expert on the formulation and commercialization of botanical-based products, will be participating on the Lift Expo panel on "Ancillary Services in the Cannabis Space: Overlooked Opportunities and Next Steps" and Abattis will be manning a booth at the Lift Expo. We welcome shareholders and attendees to come by and chat with us.

Abattis also announces that, further to its news release dated December 12, 2017, it is anticipated that Frank Zhu will be engaged as technology advisor to Abattis. Mr. Zhu has been instrumental in the development of Abattis's column chromatography extraction technology, which is capable of extraction on an industrial scale, delivers significant cost advantages, separates cannabinoids on a molecular level and extracts pure isolates such as CBD and THCA while separating pesticides from biomass. We look forward to working more closely with Mr. Zhu, as the industry tends towards a commoditization of marijuana and hemp and downstream services such as extraction become an increasingly important focus.

Abattis also announces the resignation of Dr. Shuang Xie as chief technology officer and a director of the Company. We thank Dr. Xie for her contributions to the Company and wish her all the best in her future endeavours.

About Abattis Bioceuticals Corp.

Abattis is a life sciences and biotechnology company which aggregates, integrates, and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols, and adheres to the applicable laws of Canada and foreign jurisdictions.

ON BEHALF OF THE BOARD,
ABATTIS BIOCEUTICALS CORP,

"Rob Abenante"
Robert Abenante, President & CEO

For more information, please visit the Company's website at: www.abattis.com or www.northernvinelabs.com

For inquiries, please contact the Company at (604) 336-0881 or at [email protected].

FORWARD LOOKING INFORMATION

This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "intends", "should", "believe" and similar expressions are intended to identify forward-looking statements. Forward-looking statements in this press release include statements regarding: the benefits of Abattis's column chromatography extraction technology and Mr. Zhu's engagement by the Company. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties, including: that the development Abattis's column chromatography extraction technology will not progress as expected; that Mr. Zhu will not be engaged by the Company or that such engagement will not benefit the Company as expected; that the Company will not be able to execute its proposed business plan in the time required or at all due to regulatory, financial or other issues; that the Company's competitors may develop competing technologies; changes in regulatory requirements; and other factors beyond the Company's control. Additional risk factors are included in the Company's Management's Discussion and Analysis, available under the Company's profile on www.sedar.com. The forward-looking statements are made as at the date hereof and the Company disclaims any intent or obligation to publicly update any forward-looking statements, where because of new information, future events or results, or otherwise, except as required by applicable securities laws.


© Newsfilecorp 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABATTIS BIOCEUTICALS CORP
01/12 Abattis Announces Presence at 2018 Lift Cannabis Expo and Provides Corporate ..
01/12 ABATTIS BIOCEUTICALS : Announces Presence at 2018 Lift Cannabis Expo and Provide..
01/11 Abattis Enters Into Definitive Agreement to Acquire Green Tree Therapeutics
01/10 Abattis Successfully Closes $6.9 Million Private Placement and Announces New ..
01/10 ABATTIS BIOCEUTICALS : Successfully Closes $6.9 Million Private Placement and An..
01/09 ABATTIS BIOCEUTICALS : IIROC Trade Resumption - ATT
01/09 ABATTIS BIOCEUTICALS : IIROC Trading Halt - ATT
01/09 Abattis Announces LOI for Partnership with Alliance of Beverage Licensees
01/04 Abattis Successfully Closes $6.7 Million Private Placement and Announces New ..
01/04 ABATTIS BIOCEUTICALS : Successfully Closes $6.7 Million Private Placement and An..
More news
News from SeekingAlpha
01/06 259 Marijuana Stocks, Horizons Marijuana Life Sciences Index ETF, And Jeff Se..
2017 244 MARIJUANA STOCKS : Year-End Equal-Weighted Portfolio At Only 75% Of Year-To-..
2017 Top-Performing Marijuana Stocks Of December
2017 244 MARIJUANA STOCKS : Buying The Winners And Tracking The Losers For 2018
2017 243 MARIJUANA STOCKS : A Focus On My Seeking Alpha Marijuana Portfolio And Insti..
Chart ABATTIS BIOCEUTICALS CORP
Duration : Period :
Abattis Bioceuticals Corp Technical Analysis Chart | ATT | CA00258G1037 | 4-Traders
Managers
NameTitle
Robert Abenante President, Chief Executive Officer & Director
Rene David Director, Chief Operating & Financial Officer
Shuang Xie Director & Chief Technology Officer
Douglas J. Sorocco Non-Executive Director
Guy P. Dancosse Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABATTIS BIOCEUTICALS CORP9.09%0
GILEAD SCIENCES14.10%106 002
REGENERON PHARMACEUTICALS-0.50%39 890
VERTEX PHARMACEUTICALS4.76%39 754
GENMAB10.50%11 455
BLUEBIRD BIO INC2.25%8 346